KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
08 oct. 2024 07h00 HE | KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
14 août 2024 07h00 HE | Achilles Therapeutics PLC
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa...
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
08 juil. 2024 20h00 HE | Io Therapeutics, Inc.
Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
12 juin 2024 07h00 HE | KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
09 nov. 2023 16h05 HE | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
BES_Mark.jpg
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
29 déc. 2022 21h02 HE | Bragar Eagel & Squire
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
06 oct. 2022 16h05 HE | Lyell Immunopharma, Inc
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
09 nov. 2021 08h00 HE | Achilles Therapeutics PLC
- Oral Presentation at European Society for Gene and Cell Therapy (ESGCT) demonstrated ability to generate potent anti-cancer cell therapy candidates in multiple solid tumor types - - Society for...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
22 oct. 2021 07h30 HE | Achilles Therapeutics PLC
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
01 juil. 2021 08h00 HE | Achilles Therapeutics PLC
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic...